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ABSTRACT
Malacoplakia is a rare inflammatory condition most often affecting the genitourinary system. We 
report the case of a 24-year-old man who presented with gross hematuria, nocturia, frequency, 
dysuria and considerable weight loss during the preceding three months. Digital rectal examination 
showed a solid pelvic mass. Ultrasonography and computed tomography showed calyceal 
dilatation on the right side and a solid bladder mass 10 cm in diameter suspicious of bladder cancer. 
Transurethral resection of the tumor was incomplete, due to the large volume of the bladder mass. 
Histological examination of the resected specimen revealed malacoplakia of the bladder. The 
patient was treated with fluoroquinolone and vitamin C. Follow-up at 3 months showed marked 
regression of the bladder mass and complete resolution of the calyceal dilatation. 
Key Words: Malacoplakia, bladder, pseudotumor, antibiotics.                                                                                             
Corresponding Author:  Dr Abdelghani AMMANI,  No.772, Hay El Manzah C.Y.M,  Rabat, Morocco, 
e-mail: ammani-1@hotmail.com                 
Article Info :     Date received: 25/5/2008                       Date accepted (after revision): 14/1/2009
INTRODUCTION                                                    
First described in 1902 by Michaelis and 
Gutmann1, malacoplakia is a rare, benign in-
flammatory disease mostly affecting the gen-
itourinary system2. The diagnosis is exclu-
sively based on histological examination and 
treatment consists of a combination of long-
term antibiotic therapy, cholinergic agonists 
and/or ascorbic acid (vitamin C). We report 
a case of pseudotumoral malacoplakia of the 
bladder in a 24-year-old man which was clin-
ically misdiagnosed as bladder malignancy.
CASE REPORT                                      
A 24-year-old-man was admitted to our 
department for gross hematuria associated 
with nocturia, frequency and dysuria. The 
patient also complained of intermittent 
limping with psoitis pain and weight loss 
of 14 kg during the preceding 3 months. 
Digital rectal examination showed a solid 
pelvic mass. Ultrasonography demonstrated 
calyceal dilatation on the right side and a 
homolateral solid mass in the bladder, 10 cm 
in diameter. Computed tomography (CT) was 
suggestive of a localized bladder tumor (Fig. 
1).
Voiding cystourethrography revealed a 
large filling defect arising from the bladder 
Fig.1: CT showing a solid mass in the right bladder wall.
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urinary tract2,4. In the genitourinary form of 
the disease, the bladder is most commonly 
affected (70%), followed by isolated upper 
urinary tract lesions (15%) and combined 
upper and lower tract lesions (15%)4. It is 
more common in females (sex-ratio: 4:1) 
with a peak of incidence around 50 years of 
age3,5. Malacoplakia is very rare in children6,7 
and its incidence is probably underestimated 
in adults8. 
Tumoral malacoplakia of the bladder is an 
exceptional condition9,10. There is no imaging 
technique that can diagnose malacoplakia 
with certainty. Ultrasound may demonstrate 
renal dilatation or hyperechoic lesions, while 
the bladder may be small and contracted with 
soft tissue masses10. CT scan and magnetic 
resonance imaging (MRI) findings are also 
non-specific. Malignant bladder tumors re-
present the main differential diagnosis. 
The diagnosis is exclusively histologi-
cal after biopsy or TURBT. Malacoplakia is 
characterized by aggregates of large macro-
phages with foamy eosinophilic cytoplasm 
that are present at the sites of infection and 
exhibit numerous secondary lysosomes (von 
Hansemann cells). The fusion and calcifica-
tion of these lysosomes result in the forma-
tion of intracytoplasmic crystalline bodies 
with a central hydroxyapatite core (patho-
gnomonic Michaelis-Gutmann bodies) that 
give the macrophages a concentric target-like 
appearance1,11. 
wall and a grade-1 vesicoureteral reflux on the 
left. Urine culture revealed E. coli infection.
Based on these findings a malignant 
bladder tumor was diagnosed, and we decided 
to perform a transurethral resection of the 
bladder tumor (TURBT). Cystoscopic findings 
showed a yellow-white, soft mass with central 
umbilication. The bladder tumor could not 
be resected completely because of its large 
volume, which made it difficult to identify the 
bladder wall. We therefore decided to wait for 
the results of histological examination before 
completing resection of the residual tumor or 
performing total cystectomy. Surprisingly, the 
histological changes were consistent with  
malacoplakia of the bladder (Fig. 2).
The patient was then discharged and 
treated medically with fluoroquinolone and 
vitamin C. He remained asymptomatic, and 
CT done three months later revealed marked 
regression of the bladder mass and complete 
resolution of the calyceal dilatation (Fig. 3). 
The urine culture was negative on follow-up.
DISCUSSION                                                             
Malacoplakia has been reported in 
various sites (gastrointestinal and respiratory 
tract, retroperitoneum, skin, adrenal gland, 
tonsils, conjunctiva and pancreas)3, but in 
the majority of cases (75%) it involves the 
Fig. 2: Photomicrograph showing  large macrophages with 
foamy eosinophilic cytoplasm (von Hansemann cells) and 
intracytoplasmic crystalline bodies (Michaelis-Gutmann 
bodies) (HE x 400). 
Fig. 3:  Control CT 3 months after antibiotic therapy showing 
marked regression of the bladder mass.
109
PSEUDOTUMORAL MALACOPLAKIA OF THE BLADDER 
The etiology is most likely an acquired 
defect in the bactericidal function of the 
macrophages that may result in incompletely 
digested bacterial fragments which undergo 
subsequent mineralization2,12,13. It is believed 
that the disease may be related to defective 
lysosomes and an abnormal microtubular 
assembly, similar to that seen in the 
Chediac-Higashi syndrome12. Microtubules 
are responsible for normal invagination 
and degranulation of lysosomes which are 
essential steps in the killing of bacteria by 
phagocytosis13. Alterations in the redox state 
with a reduction in the cGMP/cAMP ratio 
may be the main defect in malacoplakia1. 
Cholinergic agents enhance cGMP and beta 
glucuronidase, whereas vitamin C reduces 
cAMP. These agents can therefore be 
therapeutically effective in malacoplakia1,3,13. 
Malacoplakia has also been observed in 
association with immunocompromise, 
suggesting a disorder of the immune 
system5. Most of the cases of malacoplakia 
affecting the genitourinary system (90%) 
are associated with coliform infection, with 
E. coli being the most frequently isolated 
organism (72%)1. Various other possible 
causes of malacoplakia (prolonged treatment 
with systemic corticosteroids, tuberculosis, 
sarcoidosis, fungal or viral infection, and 
neoplasia) have been proposed14. We postulate 
that vesicoureteral reflux in our patient 
resulted in chronic bacteriuria with E. coli. 
The association of malacoplakia with 
carcinoma or tuberculosis is classically 
described and can be observed in all organs, 
but specifically in the colorectal region. 
Malacoplakia confined to the lower 
urinary tract can usually be treated medically. 
Persistent masses may require resection 
and/or the insertion of a ureteral stent if 
there is obstruction. In our patient resection 
allowed excluding the presence of bladder 
malignancy, reducing the volume of the 
bladder mass and clearing the right ureter. 
Antibiotics that achieve high intracellular 
levels such as quinolones, trimethoprim 
and rifampicin, have been shown to be 
most effective1. Quinolones are effective 
in 80% to 90% of cases. Trimethoprim 
and rifampicin are useful over prolonged 
periods. The addition of bethanecol chloride 
(Urecholine) and/or vitamin C may enhance 
phagocytic bactericidal activity1,3,13,15. Any 
immunosuppressive medications should be 
discontinued, if possible5. 
Monitoring of the patients should be 
extended because of the risk of recurrence. 
In this patient close follow-up and the 
maintenance of sterile urine have resulted in 
a marked regression of the vesical mass. 
In conclusion, malacoplakia is a rare 
benign inflammatory condition which affects 
the genitourinary system in the majority of 
cases. Tumoral malacoplakia of the bladder 
is very rare and may be misdiagnosed as 
a malignant bladder tumor. Diagnosis is 
exclusively based on histology. Malacoplakia 
confined to the lower urinary tract is usually 
treated medically, but persistent or very large 
masses may require resection.                         
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